A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects 18 Years of Age With Perennial Allergic Rhinitis (PAR)
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Fluticasone furoate (Primary) ; Mometasone
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 22 Aug 2007 Status changed from recruiting to completed.
- 24 Dec 2005 New trial record.